CyberKnife Stereotactic Accelerated Partial Breast Irradiation (SAPBI)
This study will prospectively evaluate the technical feasibility, acute toxicity, late effects and oncologic outcomes of CyberKnife Stereotactic Accelerated Partial Breast Irradiation (CK-SAPBI) in early stage breast cancer. It will evaluate quality of life (QOL) issues as they relate to treatment-related side effects and cosmetic results.
Breast Cancer|DCIS|Invasive Ductal Carcinoma
RADIATION: CK Stereotactic Accelerated Partial Breast Irradiation
The Primary Endpoint for This Study is the Percentage of Enrolled Subjects in Whom CyberKnife SAPBI PBI is Technically Feasible to Deliver and Complete Treatment, Only one of two patients were able to undergo CyberKnife SAPBI. We are measuring the percentage of enrolled subjects in whom CyberKnife SAPBI PBI is technically feasible to deliver and complete treatment, Enrollment to 24 months|Feasibility, How many patients were able to undergo CK SAPBI, 2 years
Ipsilateral Breast Recurrence, No patients have recurred to date., 1 month post radiation treatment through 5 years post treatment
This study will determine the feasibility, acute and late toxicity as well as oncologic outcomes following CK-SAPBI.